Treats homocystinuria. ANDA 214864, held by Novitium Pharma. Betaine.
As of Nov 16, 2026, ANDA 214864 (Betaine), held by Novitium Pharma, was first approved by FDA on Nov 23, 2021, with 0 approved supplements and 0 published complete response letters.
Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect Betaine Anhydrous for Oral Solution is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Betaine1GM/SCOOPFUL · for solution;oral | Betaine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters